ArticleMaterials today. Bio2026
A zinc organic metal skeleton vaccine for lung cancer treatment can stimulate strong innate and adaptive anti-tumor immunity.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumor-associated macrophages (TAMs) function as central regulators bridging innate and adaptive immunity in the tumor microenvironment (TME). Therapeutic targeting of TAMs to promote M1 polarization represents a critical strategy for tumor suppression. Methods: Herein, we engineered a zinc metal-organic framework functionalized with mannose (MAN) and loaded with CLDN6 antigen (Zn-MAN@CLDN6). We systematically evaluated the anti-tumor efficacy and immunomodulatory functions of Zn-MAN@CLDN6 both Results: The vaccine targeted the highly expressed CD206 receptor on the surface of macrophages through surface modified mannose (MAN), achieving the selective endocytosis. Its acid responsive framework can rapidly degrade under acidic conditions of macrophage lysosomes, releasing Zn Conclusion: This study developed a nano vaccine platform that integrated targeted delivery, immune regulation, and specific anti-tumor response, providing a new strategy for immunotherapy of CLDN6
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.